v3.25.3
Consolidated Statement of Profit or Loss - AUD ($)
$ in Thousands
 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
 [3]
Jun. 30, 2023
 [3]
Consolidated Statement of Profit or Loss [Abstract]      
Revenue [1],[2] $ 223,365 $ 200,873 $ 0
Other income 11,320 6,131 4,273
Expenses, excluding impairment and write down of non-financial assets (347,747) (309,006) (25,794)
Impairment and write down of non-financial assets [4] (271,310) (17,066) 0
Loss from operations (384,372) (119,068) (21,521)
Financial income 4,524 7,668 16,327
Financial expenses (4,882) (4,046) (1,506)
Net financial income/(expense) (358) 3,622 14,821
Loss before income tax (384,730) (115,446) (6,700)
Income tax benefit/(expense) 2,989 (3,576) (3,649)
Loss after income tax (381,741) (119,022) (10,349)
Attributable to:      
Equity holders of Elevra Lithium Limited (294,290) (101,398) (11,048)
Non-controlling interests $ (87,451) $ (17,624) $ 699
Earnings per share      
Basic earnings per share (in dollars per share) $ (4.0951) $ (1.5167) $ (0.1953)
Diluted earnings per share (in dollars per share) $ (4.0951) $ (1.5167) $ (0.1953)
[1] Revenue is primarily presented by the geographical destination of the product.
[2] Revenue relates solely to the sale of spodumene concentrate from North American Lithium. Refer to Note 5 (b) for a disaggregation of revenue by primary geographical market.
[3] Refer to Note 32 for details on restatement of prior period comparatives.
[4] The total impairment and write down of $271.3 million for the year ended 30 June 2025 relates to North American Lithium. The total impairment and write down of $17.1 million for the year ended 30 June 2024 relates to the Australian operations ($5.9 million), Corporate ($5.1 million), Vallée Lithium Project ($4.0 million), and various other individually immaterial projects ($2.1 million).